CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses

References

• Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3:682-5; PMID:9176498; http://dx.doi.org/10.1038/nm0697-682
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Reports 2014; 47:122-9; PMID:24499671; http://dx.doi.org/10.5483/BMBRep.2014.47.3.283
   PubMed Web of Science ®Google Scholar
• Wang S, Chen L. Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. Current topics in microbiology and immunology 2011; 344:245-67; PMID:20582531; http://dx.doi.org/10.1007/82_2010_81
   PubMed Web of Science ®Google Scholar
• Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res 2014; 74:6441-51; PMID:25252915; http://dx.doi.org/10.1158/0008-5472.CAN-14-1768-A
   PubMed Web of Science ®Google Scholar
• Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Kong LY, Rao G, Zhou S, Heimberger AB, Gilboa E. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res 2014; 2:867-77; PMID:24938283; http://dx.doi.org/10.1158/2326-6066.CIR-14-0007
   PubMed Web of Science ®Google Scholar
• Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999; 162:5003-10; PMID:10202049
   PubMed Web of Science ®Google Scholar
• Zhang H, Merchant MS, Chua KS, Khanna C, Helman LJ, Telford B, Ward Y, Summers J, Toretsky J, Thomas EK et al. Tumor expression of 4-1BB ligand sustains tumor lytic T cells. Cancer Biology Ther 2003; 2:579-86; PMID:14614331; http://dx.doi.org/10.4161/cbt.2.5.545
   PubMed Web of Science ®Google Scholar
• McGray AJ, Bernard D, Hallett R, Kelly R, Jha M, Gregory C, Bassett JD, Hassell JA, Pare G, Wan Y et al. Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology 2012; 1:419-31; PMID:22754760; http://dx.doi.org/10.4161/onci.19534
   PubMed Web of Science ®Google Scholar
• Houot R, Kohrt H. CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunology 2014; 3:e941740; PMID:25610724; http://dx.doi.org/10.4161/21624011.2014.941740
   PubMedGoogle Scholar
• Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. ProcNatlAcadSciUSA 1989; 86:1963-7; PMID:2784565; http://dx.doi.org/10.1073/pnas.86.6.1963
   PubMed Web of Science ®Google Scholar
• Schwarz H, Tuckwell J, Lotz M. A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene 1993; 134:295-8; PMID:8262389; http://dx.doi.org/10.1016/0378-1119(93)90110-O
   PubMed Web of Science ®Google Scholar
• Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999; 162:5037-40; PMID:10227968
   PubMed Web of Science ®Google Scholar
• Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, Coukos G, Powell DJ Jr. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res 2014; 20:44-55; PMID:24045181; http://dx.doi.org/10.1158/1078-0432.CCR-13-0945
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Sem Oncol 2010; 37:508-16; PMID:21074066; http://dx.doi.org/10.1053/j.seminoncol.2010.09.008
   PubMed Web of Science ®Google Scholar
• Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190:167-72; PMID:9878117; http://dx.doi.org/10.1006/cimm.1998.1396
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011; 117:2423-32; PMID:21193697; http://dx.doi.org/10.1182/blood-2010-08-301945
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Inv 2014; 124:2668-82; PMID:24837434; http://dx.doi.org/10.1172/JCI73014
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Doff BL, Rearden RC, Leggatt GR, Mattarollo SR. NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Oncoimmunology 2015; 4:e990793; PMID:25949907; http://dx.doi.org/10.4161/2162402X.2014.990793
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res 2015; 21:3113-20; PMID:25908780; http://dx.doi.org/10.1158/1078-0432.CCR-15-0263
   PubMed Web of Science ®Google Scholar
• Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18:676-84; PMID:14961035; http://dx.doi.org/10.1038/sj.leu.2403302
   PubMed Web of Science ®Google Scholar
• Campana D, Schwarz H, Imai C. 4-1BB chimeric antigen receptors. Cancer J 2014; 20:134-40; PMID:24667959; http://dx.doi.org/10.1097/PPO.0000000000000028
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21:581-90; PMID:25939063; http://dx.doi.org/10.1038/nm.3838
   PubMed Web of Science ®Google Scholar
• Mbanwi AN, Watts TH. Costimulatory TNFR family members in control of viral infection: outstanding questions. Sem Immunol 2014; 26:210-9; PMID:24910294; http://dx.doi.org/10.1016/j.smim.2014.05.001
   PubMed Web of Science ®Google Scholar
• Halstead ES, Mueller YM, Altman JD, Katsikis PD. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol 2002; 3:536-41; PMID:12021777; http://dx.doi.org/10.1038/ni798
   PubMed Web of Science ®Google Scholar
• Lin GH, Sedgmen BJ, Moraes TJ, Snell LM, Topham DJ, Watts TH. Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease. J Immunol 2009; 182:934-47; PMID:19124736; http://dx.doi.org/10.4049/jimmunol.182.2.934
   PubMed Web of Science ®Google Scholar
• Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186:47-55; PMID:9206996; http://dx.doi.org/10.1084/jem.186.1.47
   PubMed Web of Science ®Google Scholar
• Wang J, Guo Z, Dong Y, Kim O, Hart J, Adams A, Larsen CP, Mittler RS, Newell KA. Role of 4-1BB in allograft rejection mediated by CD8+ T cells. Am J Transplant 2003; 3:543-51; PMID:12752310; http://dx.doi.org/10.1034/j.1600-6143.2003.00088.x
   PubMed Web of Science ®Google Scholar
• Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007; 178:4194-213; PMID:17371976; http://dx.doi.org/10.4049/jimmunol.178.7.4194
   PubMed Web of Science ®Google Scholar
• Zhang B, Maris CH, Foell J, Whitmire J, Niu L, Song J, Kwon BS, Vella AT, Ahmed R, Jacob J et al. Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest 2007; 117:3029-41; PMID:17853940; http://dx.doi.org/10.1172/JCI32426
   PubMed Web of Science ®Google Scholar
• Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009; 114:3431-8; PMID:19641184; http://dx.doi.org/10.1182/blood-2009-05-223958
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang Y, Niu L, Vella AT, Mittler RS. Dendritic cells and Stat3 are essential for CD137-induced CD8 T cell activation-induced cell death. J Immunol 2010; 184:4770-8; PMID:20351189; http://dx.doi.org/10.4049/jimmunol.0902713
   PubMed Web of Science ®Google Scholar
• Nozawa K, Ohata J, Sakurai J, Hashimoto H, Miyajima H, Yagita H, Okumura K, Azuma M. Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases. J Immunol 2001; 167:4981-6; PMID:11673505; http://dx.doi.org/10.4049/jimmunol.167.9.4981
   PubMed Web of Science ®Google Scholar
• Kim W, Kim J, Jung D, Kim H, Choi HJ, Cho HR, Kwon B. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15:306-14; PMID:19203721; http://dx.doi.org/10.1016/j.bbmt.2008.11.035
   PubMed Web of Science ®Google Scholar
• Kim J, Choi WS, La S, Suh JH, Kim BS, Cho HR, Kwon BS, Kwon B. Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood 2005; 105:2206-13; PMID:15522958; http://dx.doi.org/10.1182/blood-2004-06-2080
   PubMed Web of Science ®Google Scholar
• Kansu E. The pathophysiology of chronic graft-versus-host disease. Int J Hematol 2004; 79:209-15; PMID:15168586; http://dx.doi.org/10.1532/IJH97.04015
   PubMed Web of Science ®Google Scholar
• Shao Z, Schwarz H. CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol 2011; 89:21-9; PMID:20643812; http://dx.doi.org/10.1189/jlb.0510315
   PubMed Web of Science ®Google Scholar
• Langstein J, Michel J, Fritsche J, Kreutz M, Andreesen R, Schwarz H. CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol 1998; 160:2488-94; PMID:9498794
   PubMed Web of Science ®Google Scholar
• Langstein J, Schwarz H. Identification of CD137 as a potent monocyte survival factor. J Leukoc Biol 1999; 65:829-33; PMID:10380906
   PubMed Web of Science ®Google Scholar
• Langstein J, Michel J, Schwarz H. CD137 induces proliferation and endomitosis in monocytes. Blood 1999; 94:3161-8; PMID:10556203
   PubMed Web of Science ®Google Scholar
• Drenkard D, Becke FM, Langstein J, Spruss T, Kunz-Schughart LA, Tan TE, Lim YC, Schwarz H. CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB J 2007; 21:456-63; PMID:17167064; http://dx.doi.org/10.1096/fj.05-4739com
   PubMed Web of Science ®Google Scholar
• Quek BZ, Lim YC, Lin JH, Tan TE, Chan J, Biswas A, Schwarz H. CD137 enhances monocyte-ICAM-1 interactions in an E-selectin-dependent manner under flow conditions. Mol Immunol 2010; 47:1839-47; PMID:20347151; http://dx.doi.org/10.1016/j.molimm.2009.11.010
   PubMed Web of Science ®Google Scholar
• Ju S, Ge Y, Qiu H, Lu B, Qiu Y, Fu J, Liu G, Wang Q, Hu Y, Shu Y et al. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling. Int Immunol 2009; 21:1135-44; PMID:19684160; http://dx.doi.org/10.1093/intimm/dxp077
   PubMed Web of Science ®Google Scholar
• Kwajah MMS, Schwarz H. CD137 ligand signaling induces human monocyte to dendritic cell differentiation. Eur J Immunol 2010; 40:1938-49; PMID:20432236; http://dx.doi.org/10.1002/eji.200940105
   PubMed Web of Science ®Google Scholar
• Harfuddin Z, Kwajah S, Chong Nyi Sim A, Macary PA, Schwarz H. CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses. Oncoimmunology 2013; 2:e26859; PMID:24482752; http://dx.doi.org/10.4161/onci.26859
   PubMed Web of Science ®Google Scholar
• Lippert U, Zachmann K, Ferrari DM, Schwarz H, Brunner E, Latif AH, Neumann C, Soruri A. CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response. Eur J Immunol 2008; 38:1024-32; PMID:18395851; http://dx.doi.org/10.1002/eji.200737800
   PubMed Web of Science ®Google Scholar
• Jiang D, Chen Y, Schwarz H. CD137 induces proliferation of murine hematopoietic progenitor cells and differentiation to macrophages. J Immunol 2008; 181:3923-32; PMID:18768847; http://dx.doi.org/10.4049/jimmunol.181.6.3923
   PubMed Web of Science ®Google Scholar
• Jiang D, Yue PS, Drenkard D, Schwarz H. Induction of proliferation and monocytic differentiation of human CD34+ cells by CD137 ligand signaling. Stem Cells 2008; 26:2372-81; PMID:18566330; http://dx.doi.org/10.1634/stemcells.2008-0158
   PubMed Web of Science ®Google Scholar
• Tang Q, Jiang D, Alonso S, Pant A, Martinez Gomez JM, Kemeny DM, Chen L, Schwarz H. CD137 ligand signaling enhances myelopoiesis during infections. Eur J Immunol 2013; 43:1555-67; PMID:23519951; http://dx.doi.org/10.1002/eji.201243071
   PubMed Web of Science ®Google Scholar
• Palucka K, Coussens LM, O'Shaughnessy J. Dendritic cells, inflammation, and breast cancer. Cancer J 2013; 19:511-6; PMID:24270350; http://dx.doi.org/10.1097/PPO.0000000000000007
   PubMed Web of Science ®Google Scholar
• Furtner M, Straub RH, Kruger S, Schwarz H. Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia. Leukemia 2005; 19:883-5; PMID:15744355; http://dx.doi.org/10.1038/sj.leu.2403675
   PubMed Web of Science ®Google Scholar
• Shao Z, Sun F, Koh DR, Schwarz H. Characterisation of soluble murine CD137 and its association with systemic lupus. Mol Immunol 2008; 45:3990-9; PMID:18640726; http://dx.doi.org/10.1016/j.molimm.2008.05.028
   PubMed Web of Science ®Google Scholar
• Ho WT, Pang WL, Chong SM, Castella A, Al-Salam S, Tan TE, Moh MC, Koh LK, Gan SU, Cheng CK et al. Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res 2013; 73:652-61; PMID:23204227; http://dx.doi.org/10.1158/0008-5472.CAN-12-3849
   PubMed Web of Science ®Google Scholar
• Shao Z, Harfuddin Z, Pang WL, Nickles E, Koh LK, Schwarz H. Trogocytic CD137 transfer causes an internalization of CD137 ligand on murine APCs leading to reduced T cell costimulation. J Leukoc Biol 2015; PMID:25765680
   PubMed Web of Science ®Google Scholar
• Middendorp S, Xiao Y, Song JY, Peperzak V, Krijger PH, Jacobs H, Borst J. Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood 2009; 114:2280-9; PMID:19608748; http://dx.doi.org/10.1182/blood-2009-03-208215
   PubMed Web of Science ®Google Scholar
• Baessler T, Charton JE, Schmiedel BJ, Grunebach F, Krusch M, Wacker A, Rammensee HG, Salih HR. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010; 115:3058-69; PMID:20008791; http://dx.doi.org/10.1182/blood-2009-06-227934
   PubMed Web of Science ®Google Scholar
• Cheng K, Cheng Wong S, Ching Linn Y, Pock Ho L, Joo Chng W, Schwarz H. CD137 ligand signalling induces differentiation of primary acute myeloid leukaemia cells. Br J Haematol 2014; 165(1):134-44; PMID: 24428589; http://dx.doi.org/10.1111/bjh.12732
   PubMed Web of Science ®Google Scholar
• Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 2002; 168:1457-65; PMID:11801689; http://dx.doi.org/10.4049/jimmunol.168.3.1457
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu YX. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 2002; 8:1405-13; PMID:12426559; http://dx.doi.org/10.1038/nm1202-796
   PubMed Web of Science ®Google Scholar
• Foell J, McCausland M, Burch J, Corriazzi N, Yan XJ, Suwyn C, O'Neil SP, Hoffmann MK, Mittler RS. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice. Ann NY Acad Sci 2003; 987:230-5; PMID:12727643; http://dx.doi.org/10.1111/j.1749-6632.2003.tb06052.x
   PubMed Web of Science ®Google Scholar
• Foell JL, ez-Mendiondo BI, Diez OH, Holzer U, Ruck P, Bapat AS, Hoffmann MK, Mittler RS, Dannecker GE. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunol 2004; 113:89-98; PMID:15312139; http://dx.doi.org/10.1111/j.1365-2567.2004.01952.x
   PubMed Web of Science ®Google Scholar
• Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, Choi BK, Vinay DS, Kwon BS. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004; 10:1088-94; PMID:15448685; http://dx.doi.org/10.1038/nm1107
   PubMed Web of Science ®Google Scholar
• Choi BK, Asai T, Vinay DS, Kim YH, Kwon BS. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine 2006; 34:233-42; PMID:16899371; http://dx.doi.org/10.1016/j.cyto.2006.04.008
   PubMed Web of Science ®Google Scholar
• Sun Y, Blink SE, Liu W, Lee Y, Chen B, Solway J, Weinstock J, Chen L, Fu YX. Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation. J Immunol 2006; 177:814-21; PMID:16818735; http://dx.doi.org/10.4049/jimmunol.177.2.814
   PubMed Web of Science ®Google Scholar
• Polte T, Foell J, Werner C, Hoymann HG, Braun A, Burdach S, Mittler RS, Hansen G. CD137-mediated immunotherapy for allergic asthma. J Clin Invest 2006; 116:1025-36; PMID:16528411; http://dx.doi.org/10.1172/JCI23792
   PubMed Web of Science ®Google Scholar
• Lee J, Lee EN, Kim EY, Park HJ, Chang CY, Jung DY, Choi SY, Lee SK, Lee KW, Kwon GY et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Immunol Lett 2005; 101:210-6; PMID:16026855; http://dx.doi.org/10.1016/j.imlet.2005.06.001
   PubMed Web of Science ®Google Scholar
• Palma C, Vendetti S, Cassone A. Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T Cells. PloS One 2010; 5:e11019; PMID:20544034; http://dx.doi.org/10.1371/journal.pone.0011019
   PubMedGoogle Scholar
• Lee SW, Park Y, Eun SY, Madireddi S, Cheroutre H, Croft M. Cutting edge: 4-1BB controls regulatory activity in dendritic cells through promoting optimal expression of retinal dehydrogenase. J Immunol 2012; 189:2697-701; PMID:22896640; http://dx.doi.org/10.4049/jimmunol.1201248
   PubMed Web of Science ®Google Scholar
• Myers L, Takahashi C, Mittler RS, Rossi RJ, Vella AT. Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc Nat Acad Sci USA 2003; 100:5348-53; PMID:12695569; http://dx.doi.org/10.1073/pnas.0837611100
   PubMed Web of Science ®Google Scholar
• Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 2013; 210:743-55; PMID:23547098; http://dx.doi.org/10.1084/jem.20121190
   PubMed Web of Science ®Google Scholar
• Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009; 229:192-215; PMID:19426223; http://dx.doi.org/10.1111/j.1600-065X.2009.00765.x
   PubMed Web of Science ®Google Scholar
• Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 1999; 190:1535-40; PMID:10562327; http://dx.doi.org/10.1084/jem.190.10.1535
   PubMed Web of Science ®Google Scholar
• Hong HJ, Lee JW, Park SS, Kang YJ, Chang SY, Kim KM, Kim JO, Murthy KK, Payne JS, Yoon SK et al. A humanized anti–4-1BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates. J Immunother 2000; 23:613-21; PMID:11186149; http://dx.doi.org/10.1097/00002371-200011000-00002
   PubMed Web of Science ®Google Scholar
• Foell J, Strahotin S, O'Neil SP, McCausland MM, Suwyn C, Haber M, Chander PN, Bapat AS, Yan XJ, Chiorazzi N et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 2003; 111:1505-18; PMID:12750400; http://dx.doi.org/10.1172/JCI200317662
   PubMed Web of Science ®Google Scholar
• Sytwu HK, Lin WD, Roffler SR, Hung JT, Sung HS, Wang CH, Cheng TL, Tsou SC, Hsi SC, Shen KL. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J Autoimmun 2003; 21:247-54; PMID:14599849; http://dx.doi.org/10.1016/S0896-8411(03)00112-4
   PubMed Web of Science ®Google Scholar
• Kachapati K, Bednar KJ, Adams DE, Wu Y, Mittler RS, Jordan MB, Hinerman JM, Herr AB, Ridgway WM. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice. J Autoimmun 2013; 47:94-103; PMID:24145149; http://dx.doi.org/10.1016/j.jaut.2013.09.002
   PubMed Web of Science ®Google Scholar
• Vinay DS, Choi JH, Kim JD, Choi BK, Kwon BS. Role of endogenous 4-1BB in the development of systemic lupus erythematosus. Immunology 2007; 122:394-400; PMID:17608689; http://dx.doi.org/10.1111/j.1365-2567.2007.02653.x
   PubMed Web of Science ®Google Scholar
• Martinez Gomez JM, Croxford JL, Yeo KP, Angeli V, Schwarz H, Gasser S. Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling. J Neurosci 2012; 32:18246-52; PMID:23238738; http://dx.doi.org/10.1523/JNEUROSCI.2473-12.2012
   PubMed Web of Science ®Google Scholar
• Bang BR, Kim SJ, Yagita H, Croft M, Kang YJ. Inhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice. Eur J Immunol 2015; 45:886-92; PMID:25501291; http://dx.doi.org/10.1002/eji.201445174
   PubMed Web of Science ®Google Scholar
• Pauly S, Broll K, Wittmann M, Giegerich G, Schwarz H. CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol 2002; 72:35-42; PMID:12101260
   PubMed Web of Science ®Google Scholar